BRAF Mutation in Preoperative Thyroid FNA Specimens BRAF Mutation in Preoperative Thyroid FNA Specimens
Is preoperative BRAF testing useful in guiding the extent of lymph node dissection in papillary thyroid carcinoma?American Journal of Clinical Pathology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 22, 2021 Category: Consumer Health News Tags: Pathology & Lab Medicine Journal Article Source Type: news

Thyroid cancer: Warning signs of the disease you shouldn’t ignore, according to a study
THYROID cancer is diagnosed in about 3,799 people every year in the UK. But advanced technology is now capable of detecting the cancer much sooner than ever before. (Source: Daily Express - Health)
Source: Daily Express - Health - July 20, 2021 Category: Consumer Health News Source Type: news

Thyroid cancer now diagnosed with machine learning-powered photoacoustic/ultrasound imaging
(Pohang University of Science& Technology (POSTECH)) POSTECH Professor Chulhong Kim's research team performs machine learning-powered photoacoustic/ultrasound imaging for thyroid cancer classification. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 9, 2021 Category: International Medicine & Public Health Source Type: news

Thyroid cancer: A worrying gastrointestinal symptom indicating your risk of the disease
THYROID cancer can occur in both men or women at any age. Thousands of patients are being misdiagnosed due to this lesser-known gastrointestinal symptom warning. (Source: Daily Express - Health)
Source: Daily Express - Health - July 7, 2021 Category: Consumer Health News Source Type: news

Radioiodine Therapy Reduces CTCs in Thyroid Cancer Radioiodine Therapy Reduces CTCs in Thyroid Cancer
A new study found a reduction of circulating tumor cell numbers in patients with differentiated thyroid cancer after radioiodine therapy. What are the implications?Clinical Endocrinology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 2, 2021 Category: Consumer Health News Tags: Ob/Gyn & Women ' s Health Journal Article Source Type: news

Impact of High-Quality US in Patients With Thyroid Cancer Impact of High-Quality US in Patients With Thyroid Cancer
What are the differences between community ultrasound and high-quality ultrasound performed by a specialized radiologist?Clinical Endocrinology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 25, 2021 Category: Consumer Health News Tags: Diabetes & Endocrinology Journal Article Source Type: news

Controversies and consensus in thyroid cancer care
(Mary Ann Liebert, Inc./Genetic Engineering News) The American Thyroid Association, the European Association of Nuclear Medicine, the European Thyroid Association, and the Society of Nuclear Medicine and Molecular Imaging released a joint statement on three key topics addressing controversies in thyroid cancer care. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 25, 2021 Category: Cancer & Oncology Source Type: news

Thyroid cancer: The lesser-known warning sign of your risk found in the ear
THRYOID cancer is more common in people in their 30s and those aged over 60. Experiencing a particular sensation in your ear or jaw could indicate your risk. (Source: Daily Express - Health)
Source: Daily Express - Health - June 20, 2021 Category: Consumer Health News Source Type: news

Endocrine Society celebrates Supreme Court decision to uphold the Affordable Care Act
(The Endocrine Society) The Endocrine Society today praised the U.S. Supreme Court's decision to uphold the Affordable Care Act, which makes health care accessible to millions of individuals nationwide, including those with hormone health conditions such as diabetes, osteoporosis, thyroid conditions, and breast and prostate cancer. (Source: EurekAlert! - Social and Behavioral Science)
Source: EurekAlert! - Social and Behavioral Science - June 17, 2021 Category: International Medicine & Public Health Source Type: news

FDA approves selpercatinib for lung and thyroid cancers with RET gene mutations or fusions
Hematology/Oncology News Burst (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - June 11, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news

FDA approves pralsetinib for RET-altered thyroid cancers
Hematology / Oncology News Burst (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - June 11, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Filipino-Americans: Vitamin D binding protein in thyroid cancer health disparities
(Impact Journals LLC) Thyroid cancer is one of the most prevalent endocrine cancers. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 9, 2021 Category: International Medicine & Public Health Source Type: news

Targeted therapy pralsetinib safely effectively treats lung and thyroid cancers with RET alterations
(University of Texas M. D. Anderson Cancer Center) Results from the multi-cohort Phase I/II ARROW clinical trial, conducted by The University of Texas MD Anderson Cancer Center researchers, showed that a once-daily dose of pralsetinib, a highly selective RET inhibitor, was safe and effective in treating patients with advanced RET fusion-positive non-small cell lung cancer (NSCLC) and RET-altered thyroid cancer. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 9, 2021 Category: Cancer & Oncology Source Type: news

Cancer symptoms: Expert uncovers five key signs of a growing thyroid tumour
ADVANCED technology is now capable of detecting cancer much sooner than ever before. All suspected thyroid cancers should be screened by an ultrasound, sometimes followed by a biopsy, and all overseen by an expert surgeon. (Source: Daily Express - Health)
Source: Daily Express - Health - June 5, 2021 Category: Consumer Health News Source Type: news

Study finds wide variation in costs of thyroid cancer care
There's a wide variation in cost and transparency of payer-negotiated prices for thyroid cancer care, according to a study published Friday in JAMA. (Source: Health News - UPI.com)
Source: Health News - UPI.com - June 4, 2021 Category: Consumer Health News Source Type: news

Wide variation in cost and transparency of payer-negotiated prices for thyroid cancer care
(Brigham and Women's Hospital) Since Jan. 1, 2021, hospitals in the US have been required by The Centers for Medicare and Medicaid Services (CMS) to provide pricing information online about items and services. A team of researchers from Brigham and Women's Hospital and Massachusetts Eye and Ear leveraged the newly available data to analyze price transparency and price variation for the treatment of thyroid cancer. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 4, 2021 Category: International Medicine & Public Health Source Type: news

Janssen Highlights Commitment to Advancing Transformative Innovations in Oncology with Scientific Updates from Deep, Diverse Pipeline and Portfolio at ASCO and EHA Virtual Scientific Programs
June 1, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than 30 company-sponsored studies, including six oral presentations, will be featured during the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, June 4-8. Janssen presentations will include new data and updates for both approved and investigational therapeutics that are being studied for the treatment of various solid tumors and blood cancers. Immediately following ASCO, additional data will be featured during the European Hematology Association (EHA) Virtual Congress, June 9-17. A ...
Source: Johnson and Johnson - June 1, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

The LUCA device proves its readiness for a better thyroid cancer screening
(ICFO-The Institute of Photonic Sciences) The study recently published in Biomedical Optics Express and authored by members of the consortium reports on several study cases and clinical tests conducted to validate the accuracy and high quality of measurements achieved by the LUCA device. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 31, 2021 Category: Cancer & Oncology Source Type: news

Long-Term ERLEADA ® (apalutamide) Patient-Reported Outcomes Data in Metastatic Castration-Sensitive Prostate Cancer Demonstrate Maintenance of Health-Related Quality of Life for Patients
May 26, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced patient-reported outcomes (PRO) data from the pre-specified final analysis of the Phase 3 TITAN study in patients with metastatic castration-sensitive prostate cancer (mCSPC). The TITAN study previously demonstrated statistically significant improvement in overall survival (OS) after a median follow-up of 44 months in patients receiving ERLEADA® plus androgen deprivation therapy (ADT).1 The new PRO data showed that the addition of ERLEADA® to ADT maintained patients’ health-related quality of lif...
Source: Johnson and Johnson - May 26, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

AffyImmune Therapeutics' AIC100 Granted Fast Track Designation for Treating Thyroid Cancer
NATICK, Mass., May 17, 2021 -- (Healthcare Sales & Marketing Network) -- AffyImmune Therapeutics, Inc., a clinical stage biotechnology company finding safe, effective ways to use CAR T cells against solid cancers, announced today that the US Food and Drug... Biopharmaceuticals, Oncology, FDA AffyImmune Therapeutics, immunotherapy, Thyroid Cancer (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - May 17, 2021 Category: Pharmaceuticals Source Type: news

How Long Can You Live With Stage IV Thyroid Cancer?
Title: How Long Can You Live With Stage IV Thyroid Cancer?Category: Diseases and ConditionsCreated: 5/14/2021 12:00:00 AMLast Editorial Review: 5/14/2021 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - May 14, 2021 Category: Cancer & Oncology Source Type: news

Why this life sciences leader is stepping away from the CEO seat — and what she plans to do next
The CEO was a cofounder of the diagnostics company 14 years ago, starting with a thyroid cancer test that has helped more than 100,000 patients avoid surgeries. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - May 10, 2021 Category: Biotechnology Authors: Ron Leuty Source Type: news

Why this life sciences leader is stepping away from the CEO seat — and what she plans to do next
The CEO was a cofounder of the diagnostics company 14 years ago, starting with a thyroid cancer test that has helped more than 100,000 patients avoid surgeries. (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - May 10, 2021 Category: American Health Authors: Ron Leuty Source Type: news

Are There Stages of Thyroid Cancer?
Title: Are There Stages of Thyroid Cancer?Category: Diseases and ConditionsCreated: 4/30/2021 12:00:00 AMLast Editorial Review: 4/30/2021 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - April 30, 2021 Category: Cancer & Oncology Source Type: news

How Is Thyroid Cancer Detected?
Title: How Is Thyroid Cancer Detected?Category: Diseases and ConditionsCreated: 4/28/2021 12:00:00 AMLast Editorial Review: 4/28/2021 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - April 28, 2021 Category: Cancer & Oncology Source Type: news

A New Frontier in Papillary Thyroid Cancer Treatment A New Frontier in Papillary Thyroid Cancer Treatment
What is the best course of treatment for small, low-risk papillary thyroid cancer? New developments have created opportunities to deliver care in a more individualized manner.American Thyroid Association (Source: Medscape Radiology Headlines)
Source: Medscape Radiology Headlines - April 26, 2021 Category: Radiology Tags: Diabetes & Endocrinology Commentary Source Type: news

International research teams explore genetic effects of Chernobyl radiation
(NIH/National Cancer Institute) Researchers utilized genomic tools to investigate potential health effects of exposure to ionizing radiation, a known carcinogen, as a result of the 1986 Chernobyl accident. One study found no evidence that genetic changes associated with radiation exposure are passed to children, while the second study documented the genetic changes in the tumors of people who developed thyroid cancer after being exposed as children or fetuses to the radiation released by the accident. Findings are being published close to the 35th anniversary of the Chernobyl disaster. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 22, 2021 Category: Cancer & Oncology Source Type: news

Janssen Provides Update on Phase 3 ACIS Study in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with ERLEADA ® (apalutamide) and ZYTIGA® (abiraterone acetate) Plus Prednisone Combination
RARITAN, N.J., April 19, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that regulatory submissions based on the Phase 3 ACIS study, which evaluated the combination of ERLEADA® (apalutamide) and ZYTIGA® (abiraterone acetate) plus prednisone in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC), will not be pursued. As presented at the American Society of Clinical Oncology’s Genitourinary (ASCO GU) Cancers Symposium in February 2021, the ACIS study met its primary endpoint of radiographic progression-free survival (rPFS); ho...
Source: Johnson and Johnson - April 19, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

ATA Issues Guidelines for Managing Anaplastic Thyroid Cancer
Evidence - based guidelines address diagnosis, evaluation, and treatment, including early multidisciplinary care team involvement (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - April 16, 2021 Category: Cancer & Oncology Tags: Endocrinology, Oncology, Pathology, Pharmacy, Radiology, Journal, Source Type: news

ATA Issues Guidelines for Managing Anaplastic Thyroid Cancer
FRIDAY, April 16, 2021 -- In new guidelines issued by the American Thyroid Association and published in the March issue of Thyroid, recommendations are presented for the diagnosis, evaluation, and treatment of anaplastic thyroid cancer (ATC). Keith... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 16, 2021 Category: Pharmaceuticals Source Type: news

Low-Risk Thyroid Cancer: No Benefit of Postsurgical Iodine Low-Risk Thyroid Cancer: No Benefit of Postsurgical Iodine
Forgoing postoperative radioactive iodine in low-risk differentiated thyroid cancer is supported by phase 3 data.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - April 8, 2021 Category: Cancer & Oncology Tags: Diabetes & Endocrinology News Source Type: news

Outcomes in Lymph Node Metastases of Thyroid Cancer Outcomes in Lymph Node Metastases of Thyroid Cancer
Should active surveillance be considered for thyroid cancer patients with cervical lymph node metastases?Clinical Endocrinology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 2, 2021 Category: Consumer Health News Tags: Diabetes & Endocrinology Journal Article Source Type: news

Increase in Thyroid Cancer Rates Points to Overscreening Increase in Thyroid Cancer Rates Points to Overscreening
Large but variable increases in rates of papillary thyroid cancer in many countries over the past two decades may point to the"diagnostic pressure" of opportunistic high-sensitivity screening, say experts.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - March 15, 2021 Category: Cancer & Oncology Tags: Diabetes & Endocrinology News Source Type: news

First lab-grown mini-thyroids use patients' own tissue
(International Society for Stem Cell Research) To investigate potential alternative treatment strategies for patients with hypothyroidism, researchers have now for the first time succeeded in generating thyroid mini-organs in the lab. In a new study published in Stem Cell Reports, Robert Coppes and colleagues from the University of Groningen, The Netherlands, used healthy thyroid tissue from patients undergoing surgical removal of the thyroid to grow mini-thyroid organs in a lab which resembled thyroid glands in their structure and protein content. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - March 11, 2021 Category: Cancer & Oncology Source Type: news

Could Too Much Light at Night Raise Your Odds for Thyroid Cancer?
(Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - February 10, 2021 Category: Cancer & Oncology Tags: Endocrinology, Oncology, News, Source Type: news

Too Much Light at Night May Raise Odds for Thyroid Cancer
A new study ties an overabundance of nighttime artificial light with an elevated risk of thyroid cancer. (Source: WebMD Health)
Source: WebMD Health - February 10, 2021 Category: Consumer Health News Source Type: news

Could Too Much Light at Night Raise Your Odds for Thyroid Cancer?
WEDNESDAY, Feb. 10, 2021 -- Though living in a bustling urban area may have its upside, all those nighttime lights could come at a price to your health, new research suggests. The study, published online recently in Cancer, a peer-reviewed journal... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - February 10, 2021 Category: General Medicine Source Type: news

Could Too Much Light at Night Raise Your Odds for Thyroid Cancer?
Title: Could Too Much Light at Night Raise Your Odds for Thyroid Cancer?Category: Health NewsCreated: 2/10/2021 12:00:00 AMLast Editorial Review: 2/10/2021 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - February 10, 2021 Category: Cancer & Oncology Source Type: news

Janssen Announces Treatment with ERLEADA ® (apalutamide) Significantly Improved Overall Survival in Patients with Metastatic Castration-Sensitive Prostate Cancer
RARITAN, N.J., February 8, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today results from the final analysis of the Phase 3 TITAN study, which demonstrated the continued statistically significant benefit of the addition of ERLEADA® (apalutamide) to androgen deprivation therapy (ADT) in overall survival (OS) in patients with metastatic castration-sensitive prostate cancer (mCSPC), regardless of extent of disease, when compared to placebo plus ADT.[1] Results will be featured in an oral presentation at the American Society of Clinical Oncology’s Genitourinary (ASCO GU) Cance...
Source: Johnson and Johnson - February 8, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Janssen Presents Results from Phase 3 ACIS Study in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with ERLEADA ® (apalutamide) and ZYTIGA® (abiraterone acetate) Combination
RARITAN, N.J., February 8, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today results from the randomized, double-blind, placebo-controlled Phase 3 ACIS study, which met the primary endpoint of radiographic progression-free survival (rPFS) with a 31 percent reduction in the risk of radiographic progression or death in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC) receiving androgen deprivation therapy (ADT). Patients in the trial received either a combination of ERLEADA® and ZYTIGA® plus prednisone (combination arm) or placebo a...
Source: Johnson and Johnson - February 8, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Artificial Light at Night Tied to Thyroid Cancer Risk
Positive association mainly driven by incidence of papillary thyroid cancer (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - February 8, 2021 Category: Cancer & Oncology Tags: Endocrinology, Oncology, Journal, Source Type: news

Artificial Light at Night Tied to Thyroid Cancer Risk
MONDAY, Feb. 8, 2021 -- Exposure to artificial light at night (LAN) is positively associated with thyroid cancer risk, according to a study published online Feb. 8 in Cancer. Dong Zhang, Ph.D., from the University of Arkansas for Medical Sciences... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - February 8, 2021 Category: Pharmaceuticals Source Type: news

Street lamps can increase your risk of thyroid cancer by up to 55%, study shows
Researchers from the University of Texas Health Science Center looked for a link between people developing thyroid cancer and levels of artificial outdoor light. (Source: the Mail online | Health)
Source: the Mail online | Health - February 8, 2021 Category: Consumer Health News Source Type: news

Study links exposure to nighttime artificial lights with elevated thyroid cancer risk
(Wiley) People living in regions with high levels of outdoor artificial light at night may face a higher risk of developing thyroid cancer. The finding comes from a study published early online in CANCER, a peer-reviewed journal of the American Cancer Society. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - February 8, 2021 Category: International Medicine & Public Health Source Type: news

Peninsula diagnostics company Veracyte acquires Decipher Biosciences
Genomic diagnostics company Veracyte is continuing to charge hard into the cancer space with a $600 million cash-and-stock acquisition of San Diego precision oncology company Decipher Biosciences Inc. South San Francisco-based Veracyte (NASDAQ: VCVT) offers a number of genomic diagnostics for indications including lung cancer, breast cancer, thyroid cancer and interstitial lung diseases, along with a forthcoming test for lymphoma. The company's combination with Decipher would add genomic test s… (Source: bizjournals.com Health Care News Headlines)
Source: bizjournals.com Health Care News Headlines - February 4, 2021 Category: Health Management Authors: Kevin Truong Source Type: news

Janssen to Highlight Robust Solid Tumor Portfolio and Pipeline at 2021 ASCO GU
February 2, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today it will highlight the depth of its solid tumor portfolio at the American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium with 12 data presentations, including three company-sponsored oral presentations from the ERLEADA® (apalutamide) clinical development program. The virtual meeting will take place February 11-13, 2021. “We are committed to the development of innovative therapies for patients with genitourinary cancers for whom there remains a high unmet need,” said C...
Source: Johnson and Johnson - February 2, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

Global Thyroid Cancer Overdiagnosis in Children and Adolescents Global Thyroid Cancer Overdiagnosis in Children and Adolescents
The incidence of thyroid cancer among children and adolescents around the world mimics the patterns in adults, which are attributed to an"epidemic of overdiagnosis."Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - January 26, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

What Age Group Gets Thyroid Cancer
? (Source: eMedicineHealth.com)
Source: eMedicineHealth.com - January 26, 2021 Category: General Medicine Source Type: news

Consumer Health: Treating thyroid cancer
Thyroid cancer occurs in the cells of the thyroid, a butterfly-shaped gland located at the base of your neck. Your thyroid produces hormones that regulate your heart rate, blood pressure, body temperature and weight. There may be no signs or symptoms early in the disease. As thyroid cancer grows, it may cause pain and swollen [...] (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - January 25, 2021 Category: Databases & Libraries Source Type: news

Maternal thyroid disorders may increase thyroid cancer risk in children
Maternal thyroid disorders may be associated with an increased thyroid cancer risk in children, and this risk may remain elevated well into adulthood, according to a study published inThe Lancet Diabetes and Endocrinology.Healio (Source: Society for Endocrinology)
Source: Society for Endocrinology - January 21, 2021 Category: Endocrinology Source Type: news